PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.
about
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisAssociation of the miR-149 Rs2292832 polymorphism with papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese populationBisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer.CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathwayImpact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinibToward precision medicine in glioblastoma: the promise and the challenges.Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer.PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics.PDGF-induced fibroblast growth requires monounsaturated fatty acid production by stearoyl-CoA desaturase.Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling.The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.Point mutations in dimerization motifs of the transmembrane domain stabilize active or inactive state of the EphA2 receptor tyrosine kinase.Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.Unwanted acquired mutations in Ba/F3 transformation assaysThe oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart.PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.IFT20 modulates ciliary PDGFRα signaling by regulating the stability of Cbl E3 ubiquitin ligases.Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
P2860
Q26797245-8923C0FB-D4B8-4106-90F8-395021ABEF4FQ34685570-91C8ECFC-84B9-4AB7-9690-5CD5CDD2006FQ35625061-30A4B356-A02A-4770-9C69-C0738A4E86E0Q35803419-AF3956EF-581E-46BA-BD87-E224A542D0E6Q37087238-C1A64BAF-9384-4913-B941-392FE3722D1DQ38454659-9487B217-80D2-4E6A-BB65-3D4AED190246Q38756560-42E09CEF-4F70-4C88-BEA4-D3A2C5052817Q38832520-166635C4-5848-4827-9731-18311BDDC227Q38882182-C7E8C784-B65F-41D0-B86A-FAA16CA2D23FQ38886353-EE9AB13F-7FD3-4F18-92F6-2E637996853DQ38911952-5FC25158-9C60-469F-88A8-7353CDCA8BA9Q38949908-9EA1477A-C6A5-409B-ACDD-DDEF007E25C6Q39016533-17C91761-1491-488A-8310-BE442D168228Q39886331-B33CFE5E-083D-41B7-98D9-335414F32B55Q42318947-C2C694F6-5EC4-4652-AD5C-5D3806E46F7AQ42360114-438F2ABC-8919-4285-AC47-E8EEF6B81106Q42586449-FA6FB172-35D7-4080-B08E-C45975CE9912Q42819833-762462F2-9686-4A3C-BD51-B2275E501680Q47296660-34845E76-2FA3-4C0A-95BF-38B165FC408FQ47756210-057212C0-94FF-4C37-8A89-1522D5361083Q49887919-32FBF85B-5314-40F6-8E32-5F17C568244EQ58617548-0650FB15-BA2B-47BD-B0A2-9E9053DDC2F8
P2860
PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
PDGFRA alterations in cancer: ...... ction and passenger mutations.
@en
PDGFRA alterations in cancer: ...... ction and passenger mutations.
@nl
type
label
PDGFRA alterations in cancer: ...... ction and passenger mutations.
@en
PDGFRA alterations in cancer: ...... ction and passenger mutations.
@nl
prefLabel
PDGFRA alterations in cancer: ...... ction and passenger mutations.
@en
PDGFRA alterations in cancer: ...... ction and passenger mutations.
@nl
P2093
P2860
P356
P1433
P1476
PDGFRA alterations in cancer: ...... ction and passenger mutations.
@en
P2093
A A Polyansky
A Essaghir
A I Velghe
B Hallberg
C P Montano-Almendras
S Van Cauwenberghe
P2860
P2888
P304
P356
10.1038/ONC.2013.218
P407
P577
2013-06-10T00:00:00Z